MAPT and Alzheimer disease: Importantly, none of the patients exhibited CSF biomarker profiles indicative of Alzheimer’s disease, as evidenced by mean amyloid-β levels of 922.31 pg/mL ± 290.78 pg/mL and mean tau protein levels of 329.44 pg/mL ± 214.01 pg/mL.